Furthermore, it has been recommended in the revised criteria for diagnosis and staging of Alzheimer’s disease, in particular the %P-tau217 (ratio of P-tau217 to non-P-tau).50 In addition, Aβ42, Aβ40 and T-tau biomarkers were not assayed in the SIVD and FTLD groups. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.